Research into AML has demonstrated that FLT3 wild-type high-risk patients with mutations in NPM1, DNMT3A, co-occurring NPM1/DNMT3A, “activated signaling,” and “DNA methylation” genes showed improved OS with sorafenib maintenance [45]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.